Ertuğrul EŞEL, M. Tayfun TURAN, Kader KÖSE, Hüseyin OĞUZ, Fatih KARAASLAN, Pakize DOĞAN, ALİ SAFFET GÖNÜL, Seher SOFUOĞLU

Genelleşmiş anksiyete bozukluğunda plazma GABA düzeyi ve sigara içme ile ilişkisi

Amaç: Epidemiyolojik çalışmalarda sigara içme ile anksiyete bozuklukları arasında ilişki bulunduğu bildirilmesine rağmen, genelleşmiş anksiyete bozukluğu ile sigaranın ilişkisini araştıran çalışma sayısı oldukça azdır. Bu çalışmada amacımız sigara içmenin anksiyete bozukluklarında rolü olduğu kabul edilen gama-amino bütirik asit (GABA) 'in plazma düzeyleri üzerinde bir etkisi olup olmadığını ve bu suretle genelleşmiş anksiyete bozukluğunun gelişmesine katkıda bulunup bulunmadığını araştırmaktı. Yöntem: Otuz dört düzenli sigara içen (20 kadın, 14 erkek, yaş ortalaması 31.6±+6.2yıl), 32 sigara içmeyen (26 kadın, 6 erkek, yaş ortalaması 32.2±7.3 yıl) genelleşmiş anksiyete bozukluğu olan hasta ve 33 düzenli sigara içen (13 kadın, 20 erkek, yaş ortalaması 30.2±6.8yıl) ve 33 sigara içmeyen (20 kadın, 13 erkek, yaş ortalaması 29.9±5.8yıl) sağlıklı kontrol deneğinin plazma GABA konsantrasyonları spektrofotometrik olarak ölçüldü ve değerlerin istatistiksel karşılaştırmaları yapıldı. Bulgular: Sigara içen hastaların plazma GABA değerleri sigara içmeyen hastalarınkinden ve kontrollerin değerlerinden anlamlı biçimde düşük bulundu. Sigara içmeyen hastaların GABA değerlerinin de her iki kontrol grubunun değerlerinden anlamlı biçimde düşük olduğu gözlendi. Sigara içen kontrol deneklerinin GABA değerleri sigara içmeyen kontrollerinkinden farklı bulunmadı. Cinsiyetin GABA değerleri üzerine herhangi bir etkisi gözlenmedi. Sonuç: Bu çalışmanın sonuçları anksiyete bozukluklarının patogenezinde GABA sisteminin işlev bozukluğunun rolünün olabileceği ve sigara içmenin bu bozukluğu daha da artırarak anksiyete bozukluklarının gelişmesini kolaylaştırabileceği fikrini desteklemektedir.

Anahtar Kelimeler:

Kaygı bozuklukları, GABA, Nikotin, Sigara içme

Effects of smoking on plasma GABA levels in patients with generalized anxiety disorder

Objective: Although it has been reported that there is a relationship between anxiety disorders and smoking in the epidemiological studies, little is known about the effects of smoking on generalized anxiety disorder. We aimed in this study to investigate whether cigarette smoking has an effect on plasma gamma-amino butyric acid (GABA), which is accepted to involve in the anxiety disorders, and in turn, contributes to development of generalised anxiety disorder. Method: Plasma GABA concentrations were measured spectrophotometrically in 34 regularly smoking (20 females, 14 males, mean age±SD: 31.6±6.2) and 32 non-smoking (26 females, 6males, mean, age±SD: 32.2±7.3) patients with generalised anxiety disorder, and in 33 regularly smoking (13 females, 20 males, mean age±SD: 30,2±6.8) and 33 non-smoking (20 females, 13 males, mean age±SD: 29.9±5.8) healthy control subjects. Statistical comparisons were carried out. Results: It was found that plasma GABA values of the smoking patients were significantly lower than both those of the non-smoking patients and those of the controls. It was observed that plasma GABA concentrations were also significantly reduced in the non-smoking patients compared to both the smoking and non-smoking controls. There was no significant difference between GABA values of the smoking and non-smoking control subjects. It was not observed any gender effect on GABA levels. Conclusion: The results of this study support the idea that dysfunction in the GABA system may have a. role in the pathagenesis of the anxiety disorders, and cigarette smoking may exacerbate or precipitate generalised anxiety disorder via reducing GABA system activity.

Keywords:

Anxiety Disorders, GABA, Nicotine, Smoking,

PDF

___

1. Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA ve ark: Depression and the dynamics of smoking. JAMA 1990; 264:1541-1545.
2. Breslau N, Kilbey MM, Andreski P: Nicotine dependence, major depression, and anxiety in young adults. Arch Gen Psychiatry 1991; 48:1069-1074.
3. Breslau N, Kilbey MM, Andreski P: Nicotine dependence and major depression: new evidence from a prospective investigation. Arch Gen Psychiatry 1993a; 50:31-35.
4. Breslau N: Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995;25:95-101.
5. Breslau N, Peterson EL, Schultz LR, Chilcoat HD, Andreski P: Major depression and stages of smoking: a longitudinal investigation. Arch Gen Psychiatry 1998; 55: 161-166.
6. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ ve ark: Smoking and major depression: a casual analysis. Arch Gen Psychiatry 1993; 50: 36-43.
7. Ginsberg D, Hall SM, Reus VI, Munoz RF: Mood and depression diagnosis in smoking cessation. Exp Clin Psychopharmacol 1995; 3:389-395.
8. Brown RA, Lewinsohn PM, Wagner EF: Cigarette smoking, major depression and other psychiatric disorders among adolescents. J Am Acad Child Adolesc Psychiatry 1996; 12:1602-1609.
9. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA: Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-997.
10. Pohl R, Yeragani VK, Balon R, Lycaki H, McBride R: Smoking in patients with panic disorder. Psychiatry Res 1992; 43: 253-262.
11. Breslau N, Klein DF: Smoking and panic attacks: an epidemiologic investigation. Arch Gen Psychiatry 1999; 56: 1141-1147.
12. Amering M, Bankier B, Berger P, Griengl H, Windhaber J ve ark: Panic disorder and cigarette smoking behavior. Compr Psychiatry 1999; 40: 35-38.
13. Johnson JG, Cohen P, Pine DS, Klein DF, Kasen S ve ark: Association between cigarette smoking and anxiety disorders during adolescence and early adulthood. JAMA 2000; 284:2348-2351.
14. Sonntag H, Wittchen HU, Höfler M, Kessler RC, Stein MB: Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults?. Eur Psychiatry 2000; 15:67-74.
15. Beckham JC: Smoking and anxiety in combat veterans with chronic posttraumatic stress disorder: a review. J Psychoactive Drugs 1999; 31: 103-110.
16. Bejerot S, Humble M: Low prevalence of smoking among patients with obsessivecompulsive disorder. Compr Psychiatry 1999; 40: 268-272.
17. Petty F, Fulton M, Kramer GL, Kram M, Davis LL ve ark: Evidence for the segregation of a major gene for human plasma GABA levels. Mol Psychiatry 1999; 4: 587-589.
18. Stahl SM: Essential Psychopharmacology. 2. baskı, Cambridge, Cambridge University Press, 2000, s. 311-323.
19. Dorow R, Horowski R, Paschelle G, Amin M: Severe anxiety induced by FG 7142, a betacarboline ligand for benzodiazepine receptors. Lancet 1983; 2: 98-99.
20. Brodsky L: Can nicotine control panic attacks? Am J Psychiatry 1985; 142: 524.
21. Carmody TP: Affect regulation, nicotine addiction and smoking cessation. J Psychoactive Drugs 1989; 21: 331-342.
22. Jarvik ME: Beneficial effects of nicotine. Br J Addict 1991; 86: 571-575.
23. Cryer PE, Haymond MW, Santiago JV, Shah SD: Norepinephrine and epinephrine release and adrenergic mediation of smokingassociated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-577.
24. Dilsaver SC: Nicotine and panic attacks. Am J Psychiatry 1987; 144: 1245-1246.
25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd ed-revised. Washington DC, American Psychiatric Press, 1987.
26. Snaith RP, Baugh SJ, Clayden AD, Husain A, Sipple MA: The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. Br J Psychiatry 1982; 141: 518-523.
27. Roberts E: Gamma-aminobutyric acid. SP Colowick, NO Kaplan (eds): Methods in Enzymology, vol VI’da, 3. baskı, New York, Academic Press Inc, 1970, s. 610-615.
28. Teicher MH: Biology of anxiety. Med Clin North Am 1988; 72: 791-814.
29. Enna SJ: Role of gamma aminobutyric acid in anxiety. Psychopathology 1984; 17 (Suppl. 1):15-24.
30. Tallman JF, Gallager DW: The GABAergic system: a locus of benzodiazepine action. Annu Rev Neurosci 1985; 8: 21-44.
31. Breslow FM, Fankhauser MP, Potter RL: Role of gamma aminobutyric acid in antipanic drug efficacy. Am J Psychiatry 1989; 146: 353-356.
32. Freund RK, Jungschaffer DA, Collins AC, Wehner JM: Evidence for modulation of GABAergic neurotransmission by nicotine. Brain Res 1988; 453: 215-220.
33. Beani L, Bianchi C, Ferraro L: Effect of nicotine on the release of acetylcholine and aminoacids in the brain. Prog Brain Res 1989; 79: 149-155.
34. Fung YK, Reed JA: Effect of nicotine on central GABAergic system. Gen Pharmac 1988; 19: 533-536.
35. Zhu PJ, Chiappinelli VA: Nicotine modulates evoked GABAergic transmission in the brain. J Neurophysiol 1999; 82: 3041-3045.
36. Bardo MT: Neuropharmacological mechanisms of drug reward: beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 1998;12: 37-67.
37. Koob GF: Neurobiology of addiction: toward the development of new therapies. Ann N Y Acad Sci 2000; 909: 170-185.
38. Mansvelder HD, McGehee DS: Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuro 2000; 27:349-357.
39. Özkan A, Arık AC, Tezcan AE: Psikiyatrik hastalarda tütün alışkanlığı ve kafeinizm. Uludağ Üniversitesi Tıp Fakültesi Dergisi 1990; 2: 277-282.
40. Pomerlaeu CS, Pomerlaeu OF: Euphoriant effects of nicotine in smokers. Psychopharmacology 1992; 108: 460-465.
41. Fleming SE, Lombardo TW: Effects of cigarette smoking on phobic anxiety. Addict Behav 1987; 12: 195-198.
42. Breslau N, Kilbey MM, Andreski P: Vulnerability to psychopathology in nicotinedependent smokers: an epidemiologic study of young adults. Am J Psychiatry 1993b; 150:941-946.

ISSN: 1302-6631
Yayın Aralığı: Yılda 6 Sayı
Başlangıç: 2000
Yayıncı: -

Arşiv